In Battle For Power At Actelion, Major Shareholder Supports Incumbent Management
This article was originally published in The Pink Sheet Daily
BB Biotech's support is critical for Actelion to fend off activist shareholder's moves to force a sale of the group.
You may also be interested in...
Two industry heavyweights nominated to Actelion's board of directors, but analysts skeptical that changes will quickly follow.
Actelion's board vice-chairman Joe Scodari highlights 'fallacies' in activist shareholder's call for sale.
A six-part contingent value right included along with Sanofi-Aventis’ cash payment of $74 a share (about $20.1 billion) for Genzyme should enable both companies’ shareholders to share in the potential upside of Lemtrada (alemtuzumab) if it is approved as a treatment for multiple sclerosis.